Correction: Transgene launches a fundraising campaign for approximately 105 million euros

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares to specialized investors via private placement and to retail investors via the PrimaryBid platform [1][4][6] - The funds raised will primarily accelerate the development of the myvac® program, which focuses on individualized cancer vaccines, particularly for head and neck cancer [3][4][7] - The company anticipates that the net proceeds from the fundraising, combined with existing cash, will be sufficient to meet working capital requirements until early 2028 [5][9] Fundraising Details - The fundraising consists of a private placement aimed at international institutional investors and a public offering for retail investors, with TSGH committing to subscribe for at least €70 million [6][10] - A concurrent capital increase of approximately €39.4 million is reserved for TSGH, which will be executed at the same price as the private placement and PrimaryBid offering [2][32] - The private placement and PrimaryBid offering are expected to close on 26 November 2025, with trading of Transgene shares suspended on that day [6][29][20] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing clinical trials and manufacturing optimization [7][4] - About 20% will be used for R&D costs related to the myvac® program and other clinical trials, while the remainder will cover general administrative expenses [7][4] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on the Current Account Advance [8] - Following the completion of the Reserved Capital Increase, the Current Account Advance Agreement will be terminated, enhancing the company's financial stability [9][32] Expected Milestones - Key milestones for the myvac® platform include reporting important data in 2026 and 2027, with potential initiation of a Phase 3 trial in head and neck cancer [3][11][13]